Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 7.69% |
| ALLIANCE FIB | AFOP | 4.26% |
| STEIN MART I | SMRT | 3.50% |
| A M R CP | AAMRQ | 3.24% |
| SYNAPTICS IN | SYNA | 2.92% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Merck KGaA ( MKGAF ) reported fourth quarter 2012 earnings per American Depository Receipt (ADR) of $2.66, up 18.8% year over year.
Revenues for the reported quarter were up 8% year over year with currency movement boosting revenues by 1.8%.
Full year 2012 earnings per share were $9.78, up 3.5%. Revenues in 2012 increased 8.7%.
Segment Sales in Detail
The company operates under four divisions: Merck Serono, Consumer Health Care, Merck Millipore and Performance Materials.
Merck Serono’s revenues increased 7.8% in 2012, driven by strong performance in North America and the emerging markets. Due to price increases in the US, Rebif sales grew organically by 7.5% in 2012. Erbitux sales grew organically by 1.9% in 2012.
The Consumer Health Care division’s revenues decreased 4.3% in 2012, primarily due to lower sales in Europe, its largest market.
The Merck Millipore division’s revenues went up 9% in 2012. Growth was driven by positive exchange rate effects and acquisitions in the areas of cell culture media, cell imaging and microbial testing.
The Performance Materials division’s revenues jumped 14.3% in 2012 due to strong demand for liquid crystals materials.
In 2012, research and development (R&D) expenses were €1.5 billion, down 0.2%. In 2012, administration expenses were €552.2 million, up 3.1% and selling and marketing expenses were €2.4 billion, up 1.1%.
Outlook
For 2013 and 2014, Merck KGaA expects revenues to grow organically at a moderate pace.
While the company expects Rebif sales to remain stable, an additional competitior is expected to enter the market by the end of March. As a result, Rebif is expected to show growth in the first two quarters of 2013 and contract in the second half of the year. Meanwhile, Erbitux is expected to remain stable or increase slightly.
Merck KGaA carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. ( LCI - Snapshot Report ) , SIGA Technologies, Inc. ( SIGA - Snapshot Report ) and QLT Inc. ( QLTI - Snapshot Report ) look more attractive with a Zacks Rank #1 (Strong Buy).
Read the full on MKGAF
Read the full Snapshot Report on SIGA
Read the full Snapshot Report on QLTI
Read the full Snapshot Report on LCI